Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEA.

bioRxiv : the preprint server for biology·2026

Same author

Dietary and Lifestyle Patterns Among Young Patients with Lung Cancer: Analysis of Mutation-Specific Phenotypes.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Same author

Cancer During Pregnancy: Navigating Clinical and Research Challenges.

Current oncology (Toronto, Ont.)·2026

Same author

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Associations Between Two-Year Immune-Related Adverse Events and Psychological Distress and Subsequent Survival Outcomes Among ICI-Treated Survivors Diagnosed With Advanced Cancers in the US.

Psycho-oncology·2026

Same author

Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Search research articles

Related Experiment Video

Updated: May 31, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Evaluating Oncologists' Communication Strategies Regarding Molecular Testing and Immunotherapy.

Meredith Gallagher¹, Samantha Vuong¹, Bonyan Qudah¹

¹University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI.

JCO Oncology Practice

|May 29, 2026

Summary

Oncologists use varied language when discussing mismatch repair deficiency (dMMR) testing and immune checkpoint inhibitors (ICIs) for metastatic colorectal cancer. A structured approach is needed to improve patient understanding of treatment options and outcomes.

Related Experiment Videos

Last Updated: May 31, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Area of Science:

Oncology
Genomics
Cancer Research

Background:

Mismatch repair deficiency (dMMR) testing identifies metastatic colorectal cancer (mCRC) patients eligible for immune checkpoint inhibitors (ICIs).
Effective communication of molecular testing results and ICI therapy is crucial but challenging due to oncologists' varied knowledge and use of jargon, and poor patient comprehension.

Purpose of the Study:

To characterize how oncologists discuss molecular testing (specifically dMMR) and ICIs with patients.
To identify effective communication strategies for molecular testing and ICI therapy in mCRC.

Main Methods:

An observational, qualitative study conducted from 2022-2023.
Recruited US medical oncologists treating colon cancer for recorded telehealth encounters with standardized patients.
Utilized NVivo QSR 14 for transcription and content analysis of discussions.

Main Results:

21 oncologists participated, discussing dMMR and ICIs with standardized patients.
Variable terminology was used to describe mismatch repair (MMR), with 'mutation' and 'protein loss' being most common.
While most oncologists discussed ICIs, few detailed response rates (30%-70%) or severe side effects; germline testing was discussed more than next-generation sequencing.

Conclusions:

Oncologists exhibit inconsistent communication regarding MMR and ICIs, employing technical jargon and omitting critical information like response likelihood and adverse events.
A structured communication framework could enhance oncologists' ability to convey essential information about molecular testing and ICIs to patients effectively.